Literature DB >> 13129412

Ascorbic acid: useful as a buffer agent and radiolytic stabilizer for metalloradiopharmaceuticals.

Shuang Liu1, Charlie E Ellars, D Scott Edwards.   

Abstract

The goal of this study is to explore the use of ascorbic acid (AA) as a buffer agent and a radiolytic stabilizer for preparation and stabilization of radiolabeled DOTA-biomolecule conjugates. Results from a titration experiment show that 0.1 M AA solution has sufficient buffer capacity at pH 5.0 while 0.5 M AA solution is useful even at pH 6.0. The radiolabeling experiment using TA138, a DOTA-conjugated nonpeptide integrin alpha(v)beta(3) receptor antagonist, clearly demonstrates that AA is a good buffer agent for pH control and an excellent antioxidant for stabilization of metal-labeled diagnostic ((111)In) and therapeutic ((90)Y and (177)Lu) radiopharmaceuticals if the radiolabeling is performed at pH 5-6. There is no need for the additional stabilizer (e.g., gentisic acid) and buffer agent such as ammonium acetate. The anaerobic AA formulation described in this study is particularly useful for radiolabeling of small biomolecules, which are sensitive to the radiolytic degradation during radiolabeling.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 13129412     DOI: 10.1021/bc034109i

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  11 in total

Review 1.  Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides.

Authors:  Shuang Liu
Journal:  Adv Drug Deliv Rev       Date:  2008-04-23       Impact factor: 15.470

2.  Quantification of 21 metabolites of methylnaphthalenes and polycyclic aromatic hydrocarbons in human urine.

Authors:  Zheng Li; Lovisa C Romanoff; Debra A Trinidad; Erin N Pittman; Donald Hilton; Kendra Hubbard; Hasan Carmichael; Jonathan Parker; Antonia M Calafat; Andreas Sjödin
Journal:  Anal Bioanal Chem       Date:  2014-04-09       Impact factor: 4.142

3.  Production of GMP-Compliant Clinical Amounts of Copper-61 Radiopharmaceuticals from Liquid Targets.

Authors:  Alexandra I Fonseca; Vítor H Alves; Sérgio J C do Carmo; Magda Silva; Ivanna Hrynchak; Francisco Alves; Amílcar Falcão; Antero J Abrunhosa
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-07

4.  Studies into radiolytic decomposition of fluorine-18 labeled radiopharmaceuticals for positron emission tomography.

Authors:  Peter J H Scott; Brian G Hockley; Hank F Kung; Rajesh Manchanda; Wei Zhang; Michael R Kilbourn
Journal:  Appl Radiat Isot       Date:  2008-09-07       Impact factor: 1.513

5.  Preventing Radiobleaching of Cyanine Fluorophores Enhances Stability of Nuclear/NIRF Multimodality Imaging Agents.

Authors:  Reinier Hernandez; Sandra Heskamp; Mark Rijpkema; Desirée L Bos; David M Goldenberg; William J McBride; Alfred Morgenstern; Frank Bruchertseifer; Weibo Cai; Otto C Boerman
Journal:  Theranostics       Date:  2017-01-01       Impact factor: 11.556

6.  47Sc as useful β--emitter for the radiotheragnostic paradigm: a comparative study of feasible production routes.

Authors:  Katharina A Domnanich; Cristina Müller; Martina Benešová; Rugard Dressler; Stephanie Haller; Ulli Köster; Bernard Ponsard; Roger Schibli; Andreas Türler; Nicholas P van der Meulen
Journal:  EJNMMI Radiopharm Chem       Date:  2017-06-02

7.  68Ga-Labeling: Laying the Foundation for an Anti-Radiolytic Formulation for NOTA-sdAb PET Tracers.

Authors:  Henri Baudhuin; Julie Cousaert; Philippe Vanwolleghem; Geert Raes; Vicky Caveliers; Marleen Keyaerts; Tony Lahoutte; Catarina Xavier
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-10

8.  Development of [225Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC.

Authors:  Eline L Hooijman; Yozlem Chalashkan; Sui Wai Ling; Figen F Kahyargil; Marcel Segbers; Frank Bruchertseifer; Alfred Morgenstern; Yann Seimbille; Stijn L W Koolen; Tessa Brabander; Erik de Blois
Journal:  Pharmaceutics       Date:  2021-05-13       Impact factor: 6.321

9.  Optimized and Automated Radiosynthesis of [18F]DHMT for Translational Imaging of Reactive Oxygen Species with Positron Emission Tomography.

Authors:  Wenjie Zhang; Zhengxin Cai; Lin Li; Jim Ropchan; Keunpoong Lim; Nabil E Boutagy; Jing Wu; John C Stendahl; Wenhua Chu; Robert Gropler; Albert J Sinusas; Chi Liu; Yiyun Huang
Journal:  Molecules       Date:  2016-12-09       Impact factor: 4.411

10.  Production and characterization of no-carrier-added 161Tb as an alternative to the clinically-applied 177Lu for radionuclide therapy.

Authors:  Nadezda Gracheva; Cristina Müller; Zeynep Talip; Stephan Heinitz; Ulli Köster; Jan Rijn Zeevaart; Alexander Vögele; Roger Schibli; Nicholas P van der Meulen
Journal:  EJNMMI Radiopharm Chem       Date:  2019-07-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.